TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00966836
Drug: Pre-emptive mycophenolate
Normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be monitored for CMV infection and receive valganciclovir only for positive PCR or antigenemia. Mycophenolate plus standard cyclosporine and prednisone will be used for maintenance immunosuppression
Study: NCT03177902
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newly diagnosed breast cancer patients undergoing at least four cycles of chemotherapy.
Study: NCT00431990
Drug: depsipeptide
Normalized name: palmitoyl dipeptide-7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1. Dose escalation, IV, Weeklyx3 in a 4week cycle. Cohort 2A. 12mg/m2, IV, Weeklyx3 in a 4week cycle. Cohort 2B. 12mg/m2, IV, Weeklyx2 in a 3week cycle.
Study: NCT04219254
Drug: BI1206
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI-1206 administrated either IV or SC every third week. Pembrolizumab 200mg administered IV every third week as a fixed dose will be used in Phase 1 and IIa.~The mTPI2 Design will be used for both the IV and SC cohorts. ivRP2D and scRP2D to be used in Phase
Study: NCT01275352
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eplerenone 50 mg/day
Study: NCT00724334
Drug: SAR302503 (TG101348)
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally administered, once a day
Study: NCT01275352
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03059940
Drug: Anti-Smoking Drug
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline or Buproprion prescribed by study doctor with directions of when and how much of anti-smoking drug that should be taken each time.
Study: NCT00783523
Drug: Doxycycline or Placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized to Doxycycline 100mg 2x/day or Placebo 2x/day for 1 or2-weeks pre-operatively.
Study: NCT04184466
Drug: NovoRapid® Penfill®
Approvals — FDA: no, EMA: no, PMDA: no
Description: insulin aspart in doses 0.3 IU/kg
Study: NCT01277666
Drug: GSK1605786A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg twice daily, administered orally for 12 weeks
Study: NCT01277666
Drug: GSK1605786A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg once daily, administered orally for 12 weeks
Study: NCT01277666
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules, administered orally for 12 weeks
Study: NCT04226365
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg capsule Thick-It filler
Study: NCT04164199
Drug: BAT1706
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously.
Study: NCT04164199
Drug: LBL-007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously.
Study: NCT02647281
Drug: GSK3389404
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3389404 is supplied as solution for injection vial. Each vial contains 100 mg/mL of GSK3389404. It's physical appearance is clear colourless to slightly yellow solution.
Study: NCT02647281
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is supplied as solution for injection vial. It's physical appearance is clear colourless solution.
Study: NCT03291067
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo QD, oral, 12 weeks
Study: NCT04151758
Drug: Docosahexaenoic Acid Supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docosahexaenoic Acid (DHA) will be given at the dose of 500 mg/day (2 ml per day DHA RICH OIL 25% aroma mandorla FoodAR Limbiate, Italy;50% DHA oil obtained from Schyzochitrium sp ; Martek Biosciences Corporation, Columbia, Maryland, USA) to all participants of the study. DHA 2 ml will provide about 16 kcal of energy.
Study: NCT01838694
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04235140
Drug: LUM/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: LUM/IVA granules for oral administration
Study: NCT03246971
Drug: Wafermine™ 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as needed for 12 hours
Study: NCT03246971
Drug: Wafermine™ 75 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as needed for 12 hours
Study: NCT03246971
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as needed for 12 hours
Study: NCT03246971
Drug: Wafermine™ 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as needed for 12 hours
Study: NCT00315926
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin 50 mg during surgery and 10 mg every night for 3 nights
Study: NCT00315926
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a mixture of ethanol and physiological saline
Study: NCT02446977
Drug: Vitamin B2 Streuli®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4ml IV
Study: NCT01176201
Drug: SLV337 suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg experimental
Study: NCT01176201
Drug: SLV337 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 x 200 mg immediate release capsule
Study: NCT01194830
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Tablet PO QD
Study: NCT00148278
Drug: norepinephrine and dobutamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous infusion of norepinephrine titrated to maintain a mean arterial pressure at 70mmHg or more and dobutamine could be added as a continuous infusion when cardiac index was of less than 2.5 liters per squared meter of body surface
Study: NCT00148278
Drug: epinephrine plus placebo of dobutamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: epinephrine was titrated to maintain a mean arterial pressure at 70mmHg or more and placebo of dobutamine was titrated in case of a cardiac index lower than 2.5 liters per squared meters of body surface
Study: NCT03562195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given as 0.9 percent sodium chloride solution.
Study: NCT01821690
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo tablets taste and look identical to buspirone.
Study: NCT01854918
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
Study: NCT03590613
Drug: GSK2982772
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route
Study: NCT03590613
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route.
Study: NCT02475564
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg of starch
Study: NCT04961710
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo; once daily
Study: NCT03839524
Drug: TG4050
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks.
Study: NCT01491711
Drug: Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
Approvals — FDA: no, EMA: no, PMDA: no
Description: The 5-ALA HCl 20% gel is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm). During illumination a fan is used to cool the treatment site. The treatment site is covered again with Tegaderm for 2 hours after first treatment, whereupon a second illumination with the same light takes place. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs. Patients are advised to avoid direct sunlight two days after treatment.
Study: NCT01475227
Drug: 1 Solvazinc tablet, day 2 to day 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc sulphate 125mg, day 2 to day 15
Study: NCT01475227
Drug: 1 Solvazinc tablet, day 15 to day 28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc sulphate 125mg, day 15 to day 28
Study: NCT01089504
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo, same volume as active drug, by mouth daily for 4 months
Study: NCT03817684
Drug: BPN14770
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug BPN14770
Study: NCT03817684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00601510
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03041038
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02190526
Drug: placebo like asacol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00119847
Drug: Optimal Medical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-directed drug therapies after MI
Study: NCT03873883
Drug: EOS100850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT03873883
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care IV Infusion
Study: NCT00872586
Drug: olmesartan medoxomil + hydrochlorothiazide
Normalized name: hydrochlorothiazide / olmesartan medoxomil Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 20mg oral tablets + hydrochlorothiazide 12.5 mg oral tablets, once daily for up to 8 weeks
Study: NCT03918915
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile topical ophthalmic solution without active ingredient
Study: NCT02738801
Drug: GLPG1690 600 mg QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG1690 capsules, administered at a dose of 600 mg, orally QD
Study: NCT02738801
Drug: Placebo QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules, administered orally QD
Study: NCT03664297
Drug: SHR1459
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR1459 will be administered continually till disease progression or unacceptable toxicity.
Study: NCT01155713
Drug: TKI258
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03549923
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients in control group will not receive any beta-blockers, including esmolol, unless the doctor thinks there's a strong indication.
Study: NCT02192515
Drug: APD356 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of APD356 10 mg will be orally administered in fasted state.
Study: NCT02192515
Drug: APD356 XR-20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of APD356 XR-20 mg will be orally administered in fasted state.
Study: NCT02192515
Drug: APD356 10 mg matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of APD356 10 mg matching placebo will be orally administered in fasted state.
Study: NCT02192515
Drug: APD356 XR-20 mg matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of APD356 XR matching placebo will be orally administered in fasted state.
Study: NCT02192515
Drug: APD356 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets of APD356 10 mg will be orally administered in fasted state.
Study: NCT02192515
Drug: APD356 20 mg matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets of APD356 10 mg matching placebo will be orally administered in fasted state.
Study: NCT02192515
Drug: APD356 XR-20mg (orange tablet, fed state)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of APD356 XR-20 mg orange tablet will be orally administered 30 minutes after the start of a meal.
Study: NCT04559568
Drug: LY3522348
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT04559568
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT02721940
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
Study: NCT02721940
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
Study: NCT03312907
Drug: Standard therapy (Including Immunosuppressants)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy will contain stable SLE medications including immunosuppressant to be administered from baseline through Week 104.
Study: NCT03312907
Drug: Standard therapy (Excluding Immunosuppressants)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy excluding Immunosuppressant will contain anti-malarials, NSAIDs, and/or corticosteroids with prednisone dose equivalent to \<= 5 mg/day will administered through Week 104.
Study: NCT03312907
Drug: Steroid Taper
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid taper will include prednisone doses equivalent to =\< 5 mg/day in all Arms through Week 104.
Study: NCT02424396
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03784443
Drug: Iluvien 0.19 MG Drug Implant
Normalized name: Iluvien 0.19 MG Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluocinolone Acetonide Sustained Release Intravitreal Implant at Baseline Visit
Study: NCT02424708
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
Study: NCT01344213
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral single-dose of celecoxib (400 mg) and placebo(C)1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
Study: NCT01344213
Drug: Pregabalin with celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral single-dose of pregabalin (150 mg) and celecoxib (400 mg) (PC) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
Study: NCT01344213
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral single dose of placebo 2 capsules 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg
Study: NCT01338441
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4mg/Kg, IV during 20 min once
Study: NCT01338441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4mg/Kg, IV during 20 min once
Study: NCT00083889
Drug: SU011248
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg orally daily for 4 weeks and 2 weeks off treatment until progression or unacceptable toxicity
Study: NCT01930396
Drug: Placebo (for Unfractionated Heparin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Normal Saline
Study: NCT01924793
Drug: DAS181-F02 Dry Powder in Bulk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via DPI
Study: NCT01924793
Drug: DAS181-F02 Nebulized Formulation Inhaled Dose
Normalized name: Hydra-Neb Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via Nebulizer
Study: NCT01087151
Drug: ABT-263
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral repeating dose
Study: NCT00547508
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet taken by mouth, no more than once a day, anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
Study: NCT03558503
Drug: UGN-102
Approvals — FDA: no, EMA: no, PMDA: no
Description: UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.~The UGN-102 admixture for intravesical instillations contains 75 mg mitomycin in 56 mL admixture (1.33 mg mitomycin per 1 mL).
Study: NCT01237665
Drug: IXO regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IXO regimen is administered as following: irinotecan 160 mg/m2 i.v. (over 60-90 minutes) with oxaliplatin 100 mg/m2 i.v. (over 120 minutes) on day 1, followed by capecitabine 950 mg/m2 PO, b.i.d. on days 2-15, every 3 weeks.~Each cycle of IXO lasts 21 days, with the subsequent cycle to start on day 22.
Study: NCT00547508
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet taken by mouth, no more than once a day, anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
Study: NCT00388349
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02395458
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient receive Omeprazole plus amoxicillin during 5 days and then omeprazole plus clarithromycin and metronidazole during another 5 days
Study: NCT02395458
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient receive Omeprazole plus amoxicillin and Clarithromycin during 14 days
Study: NCT01710345
Drug: Sufentanil NanoTab 20 mcg
Normalized name: sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01710345
Drug: Sufentanil NanoTab 30 mcg
Normalized name: sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01710345
Drug: Placebo NanoTab
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03178214
Drug: Infacort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release multiparticulate formulation of hydrocortisone.
Study: NCT03851445
Drug: Screening Platform
Approvals — FDA: no, EMA: no, PMDA: no
Description: The screening study tests patient specimens to determine eligibility for participation in the biomarker-driven and non-matched sub-studies included within the Lung-MAP umbrella protocol.
Study: NCT03480529
Drug: drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs susceptible to induce arthritis, lupus, hepatitis, or capillary leak syndrom
Study: NCT02859480
Drug: Rosuvastatin 5mg
Normalized name: ROSUVASTATIN 5MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 5mg tablet, q.d., for 30 months
Study: NCT02859480
Drug: Rosuvastatin 20mg
Normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 5mg tablet, q.d., for 30 months
Study: NCT01063049
Drug: Gatorade/Miralax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatorade 64 oz (1/2 gallon), Miralax 306 g to be consumed the day before your colonoscopy as follows: Miralax 51 g at 12 noon. Gatorade 64 oz mixed with Miralax 255 g from about 5 PM to 9 PM.
Study: NCT02627508
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally administered placebo capsules
Study: NCT01063049
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two 0.4 mg folic acid pills) to be consumed the day before the colonoscopy
Study: NCT03798366
Drug: GLPG1690
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablets of GLPG1690 for oral use.
Study: NCT03798366
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablets of GLPG1690 matching placebo for oral use.
Study: NCT00999882
Drug: AZD8055
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation phase: Tablet taken orally, a single dose of AZD8055 on Day 1, followed by twice daily continuous dosing from Day 3 onwards, till discontinuation or withdrawal.Expansion phase: twice daily continuous dosing from Day 1 onwards till discontinuation or withdrawal.
Study: NCT00512928
Drug: acenocoumarol
Normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: max 5 mg per day during 10 weeks
Study: NCT01667900
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SQ in the placebo arms and to maintain the blind in the dulaglutide arms.
Study: NCT01378364
Drug: AbGn-168H
Approvals — FDA: no, EMA: no, PMDA: no
Description: single very low dose of AbGn-168H i.v.
Study: NCT01378364
Drug: AbGn-168H
Approvals — FDA: no, EMA: no, PMDA: no
Description: single low dose of AbGn-168H i.v.
Study: NCT01378364
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of Placebo i.v.
Study: NCT01378364
Drug: AbGn-168H
Approvals — FDA: no, EMA: no, PMDA: no
Description: single medium dose of AbGn-168H i.v.
Study: NCT01378364
Drug: AbGn-168H
Approvals — FDA: no, EMA: no, PMDA: no
Description: single high dose of AbGn-168H i.v.
Study: NCT01378364
Drug: AbGn-168H
Approvals — FDA: no, EMA: no, PMDA: no
Description: single low dose of AbGn-168H s.c.
Study: NCT01378364
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of Placebo s.c.
Study: NCT01378364
Drug: AbGn-168H
Approvals — FDA: no, EMA: no, PMDA: no
Description: single medium dose of AbGn-168H s.c.
Study: NCT02236026
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01468558
Drug: MAP0004
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAP0004 1.0mg via inhalation on Day 1 and Day 6 of Visit 2
Study: NCT01468558
Drug: IV DHE
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV DHE (Intravenous Dihydroergotamine Mesylate) administered at Visit 3
Study: NCT01205217
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part I (Week 1-12) Cyclophosphamide 600 mg/m2 by IV infusion on Day 1 every 21 days
Study: NCT00809627
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine 500 mg IV